A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

July 8, 2024

Study Completion Date

August 19, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

CC-99712

CC-99712

DRUG

BMS-986405

BMS-986405

Trial Locations (20)

10029

Local Institution - 106, New York

13273

Institut Paoli Calmettes, Marseille

14263

Local Institution - 103, Buffalo

28041

Local Institution - 401, Madrid

29010

Local Institution - 0505, Málaga

34232

Local Institution - 105, Sarasota

34295

CHU Montpellier - Hôpital Saint Eloi, Montpellier

37007

Local Institution - 402, Salamanca

40138

Local Institution - 501, Bologna

41013

Local Institution - 404, Sevillla

46026

Local Institution - 403, Valencia

69495

Local Institution - 305, Pierre-Bénite

75390

Local Institution - 104, Dallas

75571

Hopital Saint Antoine, Paris

92093

Local Institution - 107, La Jolla

97239

Local Institution - 101, Portland

98104

Local Institution - 102, Seattle

M5G 2M9

Local Institution - 202, Toronto

H1T 2M4

Local Institution - 201, Montreal

08036

Local Institution - 405, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04036461 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter